This was a Phase I, dose- and schedule-finding study of capivasertib with multiple expansion cohorts that included evaluation of capivasertib with fulvestrant (NCT01226316). Results from the earlier parts of the study presenting the dose-finding, recommended Phase II dose and pharmacodynamic evaluation, as well as efficacy in patients with advanced solid tumors and those with activating PIK3CA30 or AKT1 mutations, have previously been reported14,16. The final part of this study enrolled PTEN-mutant ER+ MBC patients into two subcohorts: fulvestrant naive and fulvestrant pretreated (with a maximum of 24 patients per cohort).

Note: The content above has been extracted from a research article, so it may not display correctly.



Q&A
Please log in to submit your questions online.
Your question will be posted on the Bio-101 website. We will send your questions to the authors of this protocol and Bio-protocol community members who are experienced with this method. you will be informed using the email address associated with your Bio-protocol account.



We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.